Canine Parvovirus Monoclonal Antibody is the first and only U.S. Department of Agriculture conditionally approved treatment to target parvo. The USDA has now approved the use of CPMA for passive immunity (i.e., prophylactic treatment) to prevent parvo infection in puppies exposed to the virus, expanding the potential to protect dogs from this devastating disease.
Source: ELANCO, June 27, 2025. Link.